Telmisartan Pilot Study on Treatment Resistant Schizophrenia

Summary

This study is a 4-week pilot study for subjects with Schizophrenia or Schizoaffective Disorder who have not experienced a significant relief of symptoms from current anti-psychotic medication. The Investigators hypothesize that 4 weeks of telmisartan at 80mg daily will alter blood biomarkers for inflammation and oxidative stress after 4 weeks treatment.

Timeline

Start

2019-02-01

Primary completion

2020-10-07

Completion

2020-10-07

Drugs

Indications